Qantas to Sell Jetstar Japan Stake as It Refocuses on Core Australian Operations 
Boeing Signals Progress on Delayed 777X Program With Planned April First Flight 
Tesla Launches New Model Y Variant in the US Starting at $41,990 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Jensen Huang Urges Taiwan Suppliers to Boost AI Chip Production Amid Surging Demand 
SoftBank and Intel Partner to Develop Next-Generation Memory Chips for AI Data Centers 
SpaceX Reports $8 Billion Profit as IPO Plans and Starlink Growth Fuel Valuation Buzz 
NRW Holdings Shares Surge After Securing Major Rio Tinto Contract and New Project Wins 
Elon Musk’s SpaceX Acquires xAI in Historic Deal Uniting Space and Artificial Intelligence 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
Palantir Stock Jumps After Strong Q4 Earnings Beat and Upbeat 2026 Revenue Forecast 
Oracle Plans $45–$50 Billion Funding Push in 2026 to Expand Cloud and AI Infrastructure 
Google Cloud and Liberty Global Forge Strategic AI Partnership to Transform European Telecom Services 
SpaceX Updates Starlink Privacy Policy to Allow AI Training as xAI Merger Talks and IPO Loom 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
RALEIGH, N.C., Aug. 21, 2017 -- INC Research/inVentiv Health (Nasdaq:INCR), the only fully-integrated biopharmaceutical solutions organization, today announced that Chief Financial Officer Greg Rush is scheduled to present at two upcoming investor conferences.
Mr. Rush is scheduled to present during the 2017 Wells Fargo Healthcare Conference in Boston, MA, on Wednesday, September 6, 2017, at 8:30 a.m. EDT.
Mr. Rush is scheduled to present during the 2017 Robert W. Baird Global Healthcare Conference in New York, NY, on Thursday, September 7, 2017, at 2:00 p.m. EDT.
Links to INC/inVentiv’s live presentation and archived audio replay, as well as the presentation materials, will be available via the Company’s Investor Relations website at investor.incresearch.com.
About INC Research/inVentiv Health
INC Research/inVentiv Health (Nasdaq:INCR) is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to address new market realities where clinical and commercial share expertise, data and insights to accelerate biopharmaceutical performance. With more than 22,000 employees and the ability to support customers in more than 110 countries, our global scale and deep therapeutic alignment enables INC Research/inVentiv Health to help customers successfully navigate an increasingly complex environment. For more information on our Raleigh, N.C.-based company, visit incresearch.com or inventivhealth.com.
Investor Relations Contact: Ronnie Speight Vice President, Investor Relations +1 919 745 2745 [email protected] Press/Media Contact: Danielle DeForge Senior Director, External Communications +1 781 425 2624 [email protected]
